Dr. Andrew Holden, Associate Professor and Director of Interventional Radiology at Auckland City Hospital, had conducted FSS first-in-man study of the FlexStent® in 2009. In yesterdays procedure, he implanted a 6 mm diameter x 200 mm long FlexStent® followed by overlapping a 6x150 mm and a 6x40 mm stents to treat a long, diffuse lesion in the patients femoropopliteal artery. Dr. Holden commented, "The 200 mm FlexStent® was able to be deployed across the aortic bifurcation in the contralateral SFA easily and accurately with an excellent imaging and clinical result."
During the procedure, Dr. Holden was accompanied by Bradley Beach, FSS VP of R&D and co-inventor of the FlexStent® technology. Mr. Beach added, "I was thrilled to see the confidence in which Dr. Holden used our devices for this procedure. His feedback in the 2009 first-in-man trial was instrumental in our designing the current low-deployment force system."
Dr. Holden is scheduled to transmit a live case using the FlexStent® at the TCT Conference in San Francisco on Wednesday, November 9, 2011.
About Flexible Stenting Solutions Inc.
Flexible Stenting Solutions Inc. (FSS) is a leading developer of third-generation flexible peripheral arterial, venous, neurovascular and biliary stents. Its fully connected stent has coupled technology with clinical needs by providing an atraumatic, highly durable and fatigue resistant stent with superior radial stiffness, flexibility and conformability. FSS is an ISO 13485:2003 certified company and has received regulatory approvals on several products. FSS clinical trials in the US and Japan are underway.
For further information on Flexible Stenting Solutions, please visit the company website at www.flexiblestent.com.